Literature DB >> 8497684

The relationship between severe asthma and social class.

P Littlejohns1, L D Macdonald.   

Abstract

Asthma is one of the few diseases which has been reported to be common in the higher social classes. In order to assess the relationship between severe asthma and social class we analysed a national study of disabled adults undertaken by the Office of Population Censuses and Surveys (OPCS). The study estimated that there were 5.8 million people over 16 years with some degree of disability living in private households in England and Wales. Thirteen percent of disabilities were due to respiratory disease: 6% chronic bronchitis and emphysema, 3% asthma and allergy, and 4% other respiratory diseases. Among 10,000 individuals interviewed, 338 disabled adults reported asthma as a contributing cause of their disability. Of 291 cases with social class recorded, 41 (14%) were in social classes 1 and 2, 128 (44%) in social class 3, and 122 (42%) in social classes 4 and 5. An estimate of the relationship between social class and adult asthma in the general population was derived by calculating a morbidity ratio for the different social classes. The morbidity ratio for all social classes combined equals 100: for social classes 1 and 2 it was 63 (95% confidence intervals 48, 91); 93 (95% confidence intervals 77, 109) for social class 3; and 131 (95% confidence intervals 108, 153) for social classes 4 and 5. Adults in social classes 4 and 5 were approximately twice as likely to have severe asthma as those in social classes 1 and 2. This could be as a result of differences in the prevalence or treatment of asthma among the social classes.

Entities:  

Mesh:

Year:  1993        PMID: 8497684     DOI: 10.1016/0954-6111(93)90142-m

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  16 in total

1.  Asthma prevalence and deprivation: a small area analysis.

Authors:  C Salmond; P Crampton; S Hales; S Lewis; N Pearce
Journal:  J Epidemiol Community Health       Date:  1999-08       Impact factor: 3.710

2.  Asthma and poverty.

Authors:  R J Rona
Journal:  Thorax       Date:  2000-03       Impact factor: 9.139

3.  Influence of smoking on asthmatic symptoms and allergen sensitisation in early childhood.

Authors:  S M Tariq; E A Hakim; S M Matthews; S H Arshad
Journal:  Postgrad Med J       Date:  2000-11       Impact factor: 2.401

4.  The demographic and social class basis of inequality in self reported morbidity: an exploration using the Health Survey for England.

Authors:  S Asthana; A Gibson; G Moon; P Brigham; J Dicker
Journal:  J Epidemiol Community Health       Date:  2004-04       Impact factor: 3.710

5.  Is the ratio of inhaled corticosteroid to bronchodilator a good indicator of the quality of asthma prescribing? Cross sectional study linking prescribing data to data on admissions.

Authors:  M Shelley; P Croft; S Chapman; C Pantin
Journal:  BMJ       Date:  1996-11-02

6.  Determinants of management errors in acute severe asthma.

Authors:  J Kolbe; M Vamos; W Fergusson; G Elkind
Journal:  Thorax       Date:  1998-01       Impact factor: 9.139

Review 7.  Salmeterol. An appraisal of its quality-of-life benefits and potential pharmacoeconomic positioning in asthma.

Authors:  D H Peters; D Faulds
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

8.  A national survey of asthma prevalence, severity, and treatment in Great Britain.

Authors:  D P Strachan; H R Anderson; E S Limb; A O'Neill; N Wells
Journal:  Arch Dis Child       Date:  1994-03       Impact factor: 3.791

9.  Geographical and socioeconomic variation in the prevalence of asthma symptoms in English and Scottish children.

Authors:  E Duran-Tauleria; R J Rona
Journal:  Thorax       Date:  1999-06       Impact factor: 9.139

10.  Comparison of asthmatic patients admitted to hospital from health districts experiencing high and low asthma mortality rates.

Authors:  P Littlejohns; J Hollowell; P Hayward; S Prance
Journal:  Postgrad Med J       Date:  1994-02       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.